New p53-based anti-cancer therapeutic strategies

Medical Oncology

Volumn 15, Issue 4, 1998, Pages 222-228

  Wiman, Klas G ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cancer therapy; Gene transfer; Mutant adenovirus; Mutant p53; P53; Reactivation

Indexed keywords

PROTEIN P53; VIRUS VECTOR;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; GENE THERAPY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR REGRESSION; VIRUS MUTANT;

EID: 0032448439     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02787204     Document Type: Review

References (49)

1. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996; 10: 1054-1072.
2. Hupp TR, Meek DW, Midgley CA, Lane DP. Regulation of the specific DNA binding function of p53. Cell 1992; 71: 875-886.
3. Selivanova G et al. The single stranded DNA end binding site of p53 coincides with the C-terminal regulatory region. Nucleic Acids Res 1996; 24: 3560-3567.
4. El-Deiry WS et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
5. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-816.
6. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-1677.
7. Smith ML et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 1994; 266: 1376-1380.
8. Hermeking H et al. 14-3-3σ is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997; 1: 3-11.
9. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-299.
10. Knudson CM et al. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 1995; 270: 96-99.
11. Yin C, Knudson CM, Korsmeyer SJ, Van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 1996; 385: 637-640.
12. Buckbinder L et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995; 377: 646-649.
13. Owen-Schaub LB et al. Wild type human p53 and a temperature-sensitive mutant induce fas/APO-1 expression. Mol Cell Biol 1995: 15: 3032-3040.
14. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997; 389: 300-305.
15. Chen X, Ko LJ, Jayaraman L, Prives C, p53 levels, functional domains, and DNA damage determines the extent of the apoptotic response of tumor cells. Genes Dev 1996;10: 2438-2451.
16. Walker KK, Levine AJ. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci USA 1996; 93: 15335-15340.
17. Sakamuro D, Sabbatini P, White E. Prendergast GC. The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 1997; 15: 887-898.
18. Wu X, Bayle H, Olson D, Levine AJ. The p53-mdm2 autoregulatory loop. Genes Dev 1993; 7: 1126-1132.
19. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-299.
20. Kubbutat MHG, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387: 299-303.
21. Cho Y. Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994; 265: 364-355.
22. Vousden KH. Interactions of human papilloma virus transforming proteins with the products of tumor suppressor genes. FASEB J 1994; 7: 872-879.
23. Selivanova G, Wiman KG. p53: a cell cycle regulator activated by DNA damage. Adv Cancer Res 1995; 66: 143-180.
24. Eckner R et al. Molecular cloning and functional analysis of the adenovirus E1A-associated 300kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev 1994; 8: 869-884.
25. Gu W, Shi X-L, Roeder RG. Synergistic activation of transcription by CBP and p53. Nature 1997; 387: 819-823.
26. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM. Binding and modulation of p53 by p300/CBP coactivators. Nature 1997; 387: 823-827.
27. Lowe SW, Ruley HE. Stabilization of the p53 tumor suppressor is induced by adenovirus E1A and accompanies apoptosis. Genes Dev 1993; 7: 535-545.
28. Debbas M, White E. Wild type p53 mediates apoptosis by E1A which is inhibited by E1B. Genes Dev 1993; 7: 546-554.
29. Roth JA et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996; 2: 985-991.
30. Haupt Y, Rowan S, Oren M. p53-mediated apoptosis in HeLa cells can be overcome by excess pRB. Oncogene 1995; 10: 1563-1571.
31. 1NK4a and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med 1997; 3: 313-319.
32. Yew PR, Berk AJ. Inhibition of p53 transactivation required for transformation by adenovirus early E1B protein. Nature 1992; 357: 82-85.
33. Bischoff JR et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-376.
34. Heise C et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3: 639-645.
35. Lowe SW. Progress of the smart bomb cancer virus. Nat Med 1997; 3: 606-608.
36. Halazonetis TD, Davis LJ, Kandil AN. Wild type p53 adopts a 'mutant'-like conformation when bound to DNA. EMBO J 1993; 12: 1021-1028.
37. Halazonetis TD, Kandil AN. Conformational shifts propagate form the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select mutant p53. EMBO J 1993; 12: 5057-5064.
38. Waterman JLF, Shenk JL, Halazonetis TD. The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. EMBO J 1995: 14: 512-519.
39. Hupp TR, Lane DP. Allosteric activation of latent p53 tetramers. Curr Biol 1994; 4: 865-875.
40. Takenaka I, Morin F, Seizinger BR, Kley N. Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases. J Biol Chem 1995; 270: 5405-5411.
41. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997; 90: 595-606.
42. Hupp TR, Sparks A, Lane DP. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 1995; 83: 237-245.
43. Waterman MJF, Stavridi ES, Waterman JLF, Halazonetis TD. ATM-dependent activation of p53 involves dephosphorylation o and association with 14-3-3 proteins. Nat Genet 1998; 19: 175-178.
44. Hupp TR, Meek DW, Midgley CA, Lane DP. Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res 1993; 21: 3167-3174.
45. Abarzua P et al. Restoration of the transcription activation function to mutant p53 in human cancer cells. Oncogene 1996; 13: 2477-2482.
46. Abarzua P, LoSardo JE, Gubler ML, Neri A. Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription transactivation function to mutant p53. Cancer Res 1995; 55: 3490-3494.
47. Selivanova G et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med 1997; 3: 632-638.
48. Wieczorek AM, Waterman JLF, Waterman MJF, Halazonetis TD. Structure-based rescue of common tumor-derived p53 mutants. Nat Med 1996; 2: 1143-1146.
49. Barinaga M. From bench top to bedside. Science 1997; 278: 1036-1039.